(2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl pentan-3-ol

We are (2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl pentan-3-ol CAS:809282-20-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
CAS.NO:809282-20-0
Synonyms:(2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
(2R,3S)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol
(2S,3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methyl-3-pentanol
 
Physical and Chemical Properties:
Density 1.0±0.1 g/cm3
Boiling Point 362.9±37.0 °C at 760 mmHg
Molecular Formula C15H25NO2
Molecular Weight 251.365
Flash Point 173.3±26.5 °C
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Tapentadol(CAS:175591-23-8) and Tapentadol Hydrochloride(CAS:175591-09-0).

(2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methyl pentan-3-ol


Related News: Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells.6,7-Dimethoxyquinazoline-2,4-dione CAS:28888-44-0 Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.1-isothiocyanato-4-methoxybenzene Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms.894791-46-9 The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.

Related Products
Product Name
5-fluorocytidine View Details
12-bromododec-1-ene View Details
2,6-dimethylaniline View Details
Chroman-4-one manufacturer 2-((4-(Carboxymethyl)phenoxy)methyl)benzoic acid manufacturer Biotinyl-GHK tripeptide manufacturer Kyotorphin manufacturer N-BOC-4,4-difluoro-L-proline manufacturer